

Supplementary Materials: Brexpiprazole, A Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, A Third-Generation EGFR-TKI, via Survivin Reduction

Shuhei Suzuki, Masahiro Yamamoto, Tomomi Sanomachi, Keita Togashi, Asuka Sugai, Shizuka Seino, Takashi Yoshioka, Chifumi Kitanaka and Masashi Okada






Figure S1. Expression of epidermal growth factor receptor (EGFR) in glioma stem cells (GSCs). The expression of EGFR in the GSCs was examined by immunoblot analysis. The expression of EGFR variant III (EGFRvIII) was evaluated by comparing with sample of 293T cells transfected with a plasmid for EGFRvIII overexpression.

(Figure 1c)


Survivin (A172GS, GS-NCC01)




Survivin (GS-Y01)




Survivin (GS-Y03)




Actin (A172GS, GS-NCC01)



Actin (GS-Y01)




Actin (GS-Y03)




(Figure 1d)


p-AKT (473) (A172GS)



p-AKT (473) (GS-Y01)




p-AKT (473) (GS-NCC01)



p-AKT (473) (GS-Y03)




p-AKT (308) (A172GS)




p-AKT (308) (GS-Y01)




p-AKT (308) (GS-NCC01)




p-AKT (308) (GS-Y03)



AKT (A172GS)




AKT (GS-Y01)




AKT (GS-NCC01)




AKT (GS-Y03)



p-mTOR (A172GS)




p-mTOR (GS-Y01)




p-mTOR (GS-NCC01)




p-mTOR (GS-Y03)








(Figure 1d)
p-ERK (left to right, A172GS, GS-NCC01, GS-Y01, GS-Y03)




ERK (left to right, A172GS, GS-NCC01, GS-Y01, GS-Y03)




(Figure 2)



(Figure 3)



(Figure S1)

**Figure S2.** Immunoblotting membranes.